BioSpace News Archive

Transcenta Holding Limited has presented progression free survival data by CLDN18.2 expression level from Phase I/II study of Osemitamab plus Capecitabine and Oxaliplatin as the first-line treatment of advanced gastric/gastroesophageal junction cancer at ESMO World Congress on Gastrointestinal Cancer 2023.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company, is pleased to announce the transition of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023.

Ocugen, Inc. today announced that the Company’s Chairman, CEO and Co-Founder will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.

Baudax Bio, Inc. (Nasdaq:BXRX) (“Baudax Bio” or the “Company”) today announced the acquisition of TeraImmune, a privately held a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors.

CytomX Therapeutics, Inc. today announced that it has entered into an agreement with BVF Partners L.P. (“BVF”) for a private placement that is expected to result in initial gross proceeds of approximately $30 million.

FEops announced today its new release of FEops HEARTguide™, including an AI-based anatomical analysis of MSCT images for the pre-operative planning of structural heart interventions.

PharmaEssentia Corporation today announced the publication of new results from a Phase 2 clinical study with ropeginterferon alfa-2b (marketed as BESREMi ® ) for the treatment of patients with polycythemia vera (PV).

Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor.

NLS Pharmaceutics Ltd. today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update.